Trinity Biotech plc (TRIB) — Analysis Summary
Trinity Biotech plc (TRIB) has a market cap of $5.57M with year-over-year revenue growth of +8.3%. Net margin stands at -50.7%. The stock trades at a P/E ratio of -0.2.
Key Takeaways
- Revenue changed +8.3% year-over-year
- Net margin of -50.7%
- P/E ratio of -0.2
Compared with its sector, TRIB posted revenue growth of +8.3% and trades at a P/E of -0.2.
Trinity Biotech plc (TRIB)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -2.2x — earnings do not cover interest payments
Shareholder equity is negative, which can signal balance-sheet stress.
Operating margin at -34.4% — material operating losses
Net margin at -50.7% — significant losses
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
Employees
287
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.22
Dividend Yield
3.35%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.